This is a myopic piece, focused on a regulatory issue and targeted toward investors who may be long the stock or otherwise following OvaScience (OVAS). That is to say that I won't be discussing, except where highly relevant, the other issues surrounding the stock and its next-generation technologies for improving in vitro fertilization (IVF). For investors who are less familiar with the story and want to get up to speed, I refer you to a recent SA article by a long investor, which covers much of the basics, as well as initiation reports by sell-side analysts.
The pertinent background is that OVAS has been developing the science of using a patient's own mitochondria (the energy factories in...
Only subscribers can access this article, which is part of the PRO research library covering 3,581 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: